Micromet: Initiate Coverage Background: Micromet specializes in the development of cancer drugs based on a new class of therapeutics called “bispecific antibodies.” These novel antibodies are capable of recognizing and binding two different antigens and have been termed “bispecific T-cell engagers” or BiTE antibodies. Bispecific antibodies are part of a new generation of more advanced […]
ASH Stock Preview
2011 ASH Stock Preview It’s the end of the year, which can mean only one thing- the American Society of Hematology Convention is coming up! ASH is the year’s largest meeting for researchers and investors interested in hematology, or blood cancers. This year’s convention will be held from December 9th through 12th in sunny San […]
Antibody Engineering Wars
Therapeutic antibodies have been in use for decades now, becoming a mainstay for the treatment of cancer and inflammatory diseases. The molecules have evolved quickly through scientific advancements from simple mouse antibodies to complex humanized antibody-drug conjugates. Rapid growth in this category has grabbed Big Pharma’s attention, shifting its focus away from traditional small molecule […]
Micromet Leads In Bispecific Antibodies, Watch For DARTs
Bispecific antibodies are another front in the race to modify therapeutic antibodies for increased efficacy. Unlike normal antibodies, bispecifics are able to recognize and bind two or even three different antigens. The modified antibodies have new attributes allowing them to perform functions inconceivable for standard antibodies. The pursuit of bispecific antibodies began at least two […]
